Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Double-Blind Study to Investigate the Effect of Retatrutide on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

NCT05936151 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT05936151
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05936151 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Double-Blind Study to Investigate the Effect of Retatrutide on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
July 20, 2023
Completion date
October 21, 2025
Enrollment
146 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

ckd, overweight or obesity, type 2 diabetes